Posts

Showing posts with the label woojinleelaw

[Legal Talk] "Korean Biopharma Licensing" (partnering with Korean Pharmaceutical and Biopharma Manufacturers Association)

Image
  Introducing my latest video partnering with the ‘Korean Pharmaceutical and Bio-pharma Manufacturers Association’ on 'Useful licensing tips for Biopharma companies'. Youtube video link:  https://youtu.be/SuscTNYxBRI?si=7NCsJG38FC05DPLm

"Careers outside academia: How her PhD helps Woojin Lee give legal advice to bioscience companies" (Article from Editage Insights)

Image
  An article written by Editage insights, on "Careers outside academia: How her PhD helps Woojin Lee give legal advice to bioscience companies".  Link shared below: Link  

[Legal Talk] "Korean Biopharma M&A" (partnering with Korean Pharmaceutical and Biopharma Manufacturers Association)

Image
 Introducing my latest video partnering with the ‘Korean Pharmaceutical and Bio-pharma Manufacturers Association’ on the topic of  'Korean Mergers & Acquitisions of pharmaceutical and life science companies'. Youtube video link:  https://www.youtube.com/watch?v=Pwdpyq71ngY&t=26s

Amendment of the 'Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products' welcomed by the industry

Image
On the first day of this month, the Ministry of Food and Drug Safety and the biotech industry welcomed the acceptance of the bill adding 'Regenerative Medical Institutions' as human cell management by the National Assembly, amending the 'Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products'.  Human Cell Management businesses are operators who collect, import, inspect, process, and supply human cells, which have been mostly in-house product manufacturers or the blood banks. Now that this amendment has been approved, advanced regenerative medical institutions equipped with facilities, equipment, and personnel similar to the standards for human cell management, shall also be recognized as subjects for permits for the management of human cells. This means that advanced regenerative medical institutions can supply raw materials by performing minimal procedures such as simple isolation, washing, freezing, and thawing of cells ob...

Global ADC Technology competition intensifies in South Korea

Image
The global competition for Antibody-Drug Conjugate (ADC) technology, a cutting-edge method in anti-cancer drug development, is intensifying. Major global pharmaceutical companies, including Pfizer, AbbVie, and Johnson & Johnson, invested significantly to secure ADC technology. This trend is also evident in South Korea, with companies like Samsung Biologics and Celltrion leading the race to obtain ADC capabilities. ADC involves attaching drugs that can attack cancer cells to antibodies, offering targeted drug delivery for anti-cancer agents. The technology is gaining attention globally, and the ADC market is expected to reach $19.8 billion by 2028. The interest in ADC further increased with the approval of 'Enhertu,' an ADC drug for breast cancer jointly developed by AstraZeneca and   Daiichi Sankyo. Major global pharmaceutical companies are actively involved in ADC technology, with Pfizer's Seagen acquisition being the largest M&A deal in the sector. Korean companie...

Expansion of Non-face-to-face Services · Delivery of Medications from Public Late-night Pharmacies, South Korea's Ruling Party's General Election Pledge

Image
The South Korean Government is currently proposing several measures to address regional medical disparities and improve healthcare accessibility, particularly during nighttime and holidays. Here's a summary of the key points; 1. Amendments to Medical Laws  There are proposed amendments to allow the delivery of pharmaceuticals from public late-night pharmacies for non-face-to-face consultations during evenings and holidays. 2. Establishment of Regional Medical Schools  Plans include promoting the establishment of regional medical schools to address the demand and conditions of medically underserved areas. Additionally, there is an intention to enact a 'Special Law for Resolving Regional Medical Disparities' ( 지역 의료 격차 해소 특별법)  to support this effort. 3. Improving Regional Medical Infrastructure  Efforts are underway to enhance regional hub public hospitals with advanced systems and establish a cooperative network between regional national hospitals and public hospital...

‘Co-promotion’ increases between Korean Pharmaceutical Companies

Image
As the research and development (R&D) capabilities of Korean pharmaceutical companies significantly improve and new drug development continues, the number of cases of marketing and sales collaboration, such as 'co-promotion' agreements executed for joint sales of drugs has been reported to be increasing. It was reported on the 14th of this month, that a total of 14 cases of marketing and sales collaboration between Korean pharmaceutical companies occurred this year, through co-promotion agreements for joint sales of medicines. List of Korean 'co-promotion' Agreements executed in the year of 2023 Co-promotion has the advantage of allowing developers with weak sales capabilities to leverage the capabilities of other pharmaceutical companies with strong sales capabilities in the field. One example is the joint sales of ‘Zemiglo’ by LG Chem and Daewoong Pharmaceutical, where at the time of approval, LG Chem signed a joint sales agreement with the global pharmaceutical c...

South Korea's Telemedicine Industry, where are we at?

Image
The Korean telemedicine industry has been experiencing significant growth and transformation, spurred by advancements in technology and changes in healthcare delivery models. Although so far, South Korea's regulatory environment has not been so friendly for the telemedicine industry, limiting the scope of telemedicine services, there have been many efforts to expand telemedicine regulations to accommodate technological advancements and changing healthcare needs. During the COVID pandemic, this unprecedented experience has accelerated the adoption of telemedicine globally, including in South Korea. As social distancing measures and lockdowns restricted in-person healthcare visits, telemedicine emerged as a crucial alternative for patients to receive medical advice and treatment while minimizing the risk of virus transmission. As a result, the South Korean government has recognized the potential benefits of telemedicine in improving healthcare accessibility, especially in remote area...

Introduction of Dr. Woojin Lee, J.D., Ph.D.

Image
Before starting her career as a lawyer providing legal services for Life Science and Pharmaceutical companies, Woojin earned a Ph.D. degree in Neuroscience at the University College London, Institute of Neurology, as a government scholarship recipient and a Master's degree in Oncology at the University of Nottingham,   at the School of Molecular Medical Science  in the U.K.  Woojin is a skilled advisory lawyer sought by many Life Science and Pharmaceutical companies in South Korea, based on her in-depth experience from Life Science research in the laboratory, global clinical trials and working as an IP lawyer before opening her own specialized practice in year 2020.   Woojin also has experience as a professional academic consultant in the field of English Medical Writing and has been recognized for her expertise in lectures for Medical Science Communication. ▲ J.D. at Ewha Law School, Attorney at Law, Patent Attorney (2016) ▲ Ph.D. Neuroscience...